HOUSE_OVERSIGHT_024023.jpg

molecular immunology at The Pasteur Institute and earned an M.D. and Ph.D. from the University of Paris, and an M.B.A. from Columbia University. Jeani Delagardelle, (57), Managing Director, helped found New Leaf in 2005. She joined Sprout in 2000. At New Leaf, Jeani leads the Medical Device investment effort. Jeani is currently on the boards of directors of Access Closure, Altura, Cardiokinetix, Direct Flow Medical, Intrinsic Therapeutics, ReShape Medical, and Spiracur. She was previously on the boards of directors of Interlace (NLV-I company acquired by Hologic), Epicor (acquired by St. Jude), Visiogen (acquired by Abbott), PercuSurge (acquired by Medtronic), and NxStage Medical (NASDAQ: NXTM). Prior to joining the healthcare investment team at Sprout, Jeani was a General Partner at Weiss, Peck & Greer Venture Partners (“WPGVP”) where she focused on healthcare investments. Before joining the venture industry, Jeani spent 16 years in senior marketing and general management positions in both the medical device and pharmaceutical industries. She was Vice President of Global Marketing for Target Therapeutics, held several senior management positions within the Medi-tech division of Boston Scientific, and served as the Director of Business operations for Roche Pharmaceuticals. Jeani earned an A.B. in Clinical Psychology from Occidental College and an M.B.A. from the University of California at Irvine. Ron Hunt, (49), Managing Director, joined Sprout in 1998 and helped found New Leaf in 2005. He has played significant role in the firm’s investment activities in later stage biopharmaceuticals and has also contributed to the activities in each of the other sectors. Ron is currently on the boards of Durata Therapeutics (NASDAQ: DRTX), IlluminOss Medical, Relypsa (NASDAQ: RLYP), and SpineWave. Ron was previously on the boards of Cerexa (NLV-I company acquired by Forest Laboratories), Stromedix, Inc. (NLV-I company acquired by Biogen Idec), Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica, Inc.), Phase Forward (NASDAQ: PFWD, acquired by Oracle), and Pathology Partners (acquired by Caris Group). Before joining Sprout, he spent a combined 12 years in the pharmaceutical industry in operating roles and as a management consultant with The Healthcare Group (a division of the Interpublic Group of Companies) and Coopers & Lybrand Consulting. He gained eight years of operating experience in various commercial roles working for SmithKline Beecham and Johnson & Johnson. Ron earned a B.S. from Cornell University and an M.B.A. from The Wharton School of the University of Pennsylvania. Vijay Lathi, (41), Managing Director, helped found New Leaf in 2005 and joined Sprout in 1998. Vijay’s activities are focused primarily on information convergence, although historically he has been involved in investments across all sectors. He is currently on the boards of directors of AwarePoint, Oxford Immunotech (NASDAQ: OXFP), iRhythm Technologies, Kit Check, TigerText and XDx, while maintaining board observer status with Labcyte. Vijay was previously on the boards of Advanced Cell Diagnostics, Ilypsa (acquired by Amgen) and Relypsa (NASDAQ: RLYP). Prior to joining Sprout, Vijay spent one year as an analyst in the healthcare venture capital group at Robertson Stephens where he reviewed investments spanning medical devices, therapeutics and healthcare information technology. Prior to Robertson Stephens, Vijay spent approximately one and a half years as an analyst at Cornerstone Research, a business consulting firm focused on financial and econometric analysis. He earned an M.S. in Chemical Engineering from Stanford University and a B.S. in Chemical Engineering from MIT, with a focus on applications of engineering to the life sciences. 12 CONTROL NUMBER 257 - CONFIDENTIAL HOUSE_OVERSIGHT_024023